All In Biotech

Drug Trial Radar · NCT05308953

A Phase I Safety Study of NVG-291 in Healthy Adults

A Randomized, Triple-Blind, Placebo-Controlled Phase I Study of Single and Multiple Ascending Doses of NVG-291 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jan 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

74

Actual

Start

May 6, 2021

Primary completion

Jun 4, 2023

Study completion Jul 3, 2023

Sponsor

Lead sponsor
NervGen PharmaIndustry
Sponsor type
Industry
First posted
Apr 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, triple-blind (subjects, Investigators, and Sponsor blinded), placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) study to evaluate the safety and tolerability of NVG-291 administered by subcutaneous injection daily in healthy female participants. The trial is split into three parts, starting with Part 1 (SAD), then Part 2 (MAD - post-menopausal Females), and finally Part 3 (MAD - males and premenopausal females). In Part 1 (SAD), participants receive 1 dose on 1 day only and in Parts 2 and 3, participants receive 1 dose every day for 14 days.

Conditions

  • Spinal Cord Injury

Interventions

  • NVG-291Drug

    NVG-291 is a drug injected under the skin (subcutaneous).

  • PlaceboOther

    Salt water is being used as a placebo and will be injected under the skin (subcutaneous).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: Assessed through 7 days following the last dose of study drug

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Networks

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.